Wednesday, April 4, 2018

Versant Sells Inception's Neuroscience Program To Roche

San Diego-based venture investor Versant Ventures said today that it has sold its Inception 5 program, focused on regenerative therapies for multiple sclerosis, to Roche Holdings. Financial details of the sale were not announced. According to Versant, as a result of the acquisition, it will launch a new company, Pipeline Therapeutics, a successor company led by the same operating team, to identify next generation neuro-regenerative therapies. Roche said the formation, financing, and launch of Pipeline Therapeutics will be led by manging director Clare Ozawa. The company's team will also include Drs. Brian Stearns and Daniel Lorrain from Inception 5.